
Sign up to save your podcasts
Or


Diffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma. Tune in as we chat with Dr. Yasmin Karimi from the University of Michigan about the latest breakthroughs in treatment, including combination therapies, CAR T-cell therapy and bispecific antibodies. Discover how these innovations are offering new hope and pathways to cures for patients.
Mentioned on this episode:
Additional LLS Support Resources:
Support for this episode provided by Genmab US, Inc.
The post Emerging Therapies and Hope: Diffuse Large B-cell Lymphoma first appeared on The Bloodline with Blood Cancer United Podcast.
By Blood Cancer UnitedDiffuse large B-cell lymphoma is the most common subtype of non-Hodgkin lymphoma. Tune in as we chat with Dr. Yasmin Karimi from the University of Michigan about the latest breakthroughs in treatment, including combination therapies, CAR T-cell therapy and bispecific antibodies. Discover how these innovations are offering new hope and pathways to cures for patients.
Mentioned on this episode:
Additional LLS Support Resources:
Support for this episode provided by Genmab US, Inc.
The post Emerging Therapies and Hope: Diffuse Large B-cell Lymphoma first appeared on The Bloodline with Blood Cancer United Podcast.